Webinar: Antiretroviral Therapy – 2021 Update
Facilitated by David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, Division of Infectious Diseases
University of Washington
May 12, 2021
Other Trainings
- Webinar: HIV Basics
- Webinar: Welcome to Taking a Sexual History
- Webinar: Cabotegravir/Rilpivirine Workflow Implementation and Evolution in an Ambulatory Clinic
- Webinar: Getting to 90-90-90: Development of an HIV Reengagement Team
- Webinar: Ending the HIV Epidemic – Prevention: PrEPing the South, Challenges and Innovations
Objectives
- List recommended 3-drug and 2-drug antiretroviral options for initial therapy
- Summarize available 2-drug maintenance regimens for persons with undetectable HIV RNA levels
- Discuss three new medications: Ibalizumab, Fostemsavir, and Cabotegravir-Rilpivirine
- Describe the mechanism of action for nucleoside reverse translocate transcriptase inhibitors and capsid Inhibitors
Presentation
Slides
Facilitated by David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, Division of Infectious Diseases
University of Washington
May 12, 2021
Objectives
- List recommended 3-drug and 2-drug antiretroviral options for initial therapy
- Summarize available 2-drug maintenance regimens for persons with undetectable HIV RNA levels
- Discuss three new medications: Ibalizumab, Fostemsavir, and Cabotegravir-Rilpivirine
- Describe the mechanism of action for nucleoside reverse translocate transcriptase inhibitors and capsid Inhibitors
Presentation
Slides
Other Trainings
- Webinar: HIV Basics
- Webinar: Welcome to Taking a Sexual History
- Webinar: Cabotegravir/Rilpivirine Workflow Implementation and Evolution in an Ambulatory Clinic
- Webinar: Getting to 90-90-90: Development of an HIV Reengagement Team
- Webinar: Ending the HIV Epidemic – Prevention: PrEPing the South, Challenges and Innovations
